Deals in Depth: September 2011
Executive Summary
After out-licensing the Alzheimer’s candidate several years ago, Roche took back rights to Evotec’s EVT302 in an alliance worth $180 million. Perkin Elmer paid $577 million in cash for Caliper Life Sciences, which produces molecular imaging and detection technologies. Both biopharma and medical device financing increased in September vs. August.